Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Alone or With Lenvatinib in Advanced Endometrial Cancer
NCT05112991Phase 2Recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in endometrial cancer (EC), sponsored by 3D Medicines Inc.. Started Mar 2022; status: recruiting.
02
Drugs
envafolimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05112991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112991.